Depletion of protein kinase C (PKC) by 12- O -tetradecanoylphorbol-13-acetate (TPA) enhances platinum drug sensitivity in human ovarian carcinoma cells by Isonishi, S et al.
Keywords: platinum agents; protein kinase C; drug sensitivity
Cisplatin (DDP) is active against several types of human cancer,
particularly those of the ovary, testis, bladder and the head and
neck (Loehrer and Einhorn, 1984). However, its efficacy is limited
by tumour cell resistance, present either at the onset of treatment
or evolving after an initial treatment response (Ozols and Young,
1984). Studies using isogenic pairs of sensitive and resistant cells
have shown that acquired DDP resistance is mediated by multiple
mechanisms including reduced intracellular accumulation,
elevated intracellular thiol content and increased DNA repair of
platinum-induced inter- or intrastrand DNA cross-links (Andrews
and Howell, 1990). There is substantial interest in developing
pharmacological strategies for overcoming acquired DDP resis-
tance by modulating these parameters (Schilder and Ozols, 1992);
however, at the present time the only way to achieve this is to
administer larger doses of the drug.
Participation of protein kinase C (PKC) in intracellular
signalling has been demonstrated in many cell types, including
variety of cancer cells (Hsu et al, 1998). PKC-mediated phos-
phorylation of numerous protein substrates is associated with a
wide range of biological effects, including induction of cellular
proliferation and differentiation, activation of nuclear transcription
factors and cell surface receptors, and tumour promotion (Craven
and DeRubertis, 1988; Rahmsdorf et al, 1990; Brach et al, 1992).
PKC is a family of at least nine structurally related serine/
threonine kinase isoforms differing in substrate specificity and
dependence on Ca2+ availability. Differential regulation of the
activation of different forms of PKC is not well understood.
Calcium concentrations are probably important, as one group of
isozymes (a,  bI,  bII and g) are regulated by Ca2+, phospha-
tidylserine and diacylglycerol (DAG). However, the activities of
the more recently discovered isozymes (e,  d,  h, and q) are
independent of Ca2+, and z is independent of both Ca2+ and DAG.
PKC isozyme function can be studied using antisense technology.
Balboa et al (1994) selectively reduced the levels of either PKCa
or PKCbI by transfection of kidney D1 cells with corresponding
antisense oligonucleotides. This study implicated PKCa but not
PKCbI in the activation of phospholipase C.
PKC has been identified as a high-affinity receptor for the
phorbol ester TPA (Niedel et al, 1983). 12-O-tetradecanoyl-
phorbol-13-acetate (TPA) is one of a group of tumour promoters
which can either stimulate cell proliferation or cause arrest,
depending on the type of cell which is treated and proliferative
status of the culture. Through activation of PKC, treatment of cells
with TPA can lead to a number of changes in phenotype as a result
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Summary Down-regulation of protein kinase C (PKC) by 12-O-tetradecanoylphorbol-13-acetate (TPA) enhances the sensitivity of human
ovarian carcinoma 2008 cells to various types of platinum compounds such as cisplatin (DDP), carboplatin and (–)-(R)-2-
aminomethylpyrrolidine (1,1-cyclobutanedicarboxylato)-platinum(II) monohydrate (DWA) by a factor of two- to threefold. TPA enhanced the
sensitivity of the DDP-resistant 2008/C13*5.25 subline to each of these three drugs to the same extent as for the 2008 cells. The extent of
PKC down-regulation and drug sensitization depended on the duration of TPA exposure; maximum effect was achieved with a 48 h
pretreatment. Sensitization was TPA concentration-dependent and was maximal at 0.05 mM TPA. 2008 cells expressed only the PKCa and
PKCz isoforms. Western blot analysis revealed that whereas the expression of PKCa was reduced by TPA the level of PKCz was not affected.
These results suggest that PKCa is the isotype responsive to TPA in these cells and that platinum drug sensitivity can be modulated by this
isoform alone. In parallel to its effect on PKCa, TPA decreased cellular glutathione content by 30 ± 3 (standard deviation (s.d.) % in 2008 cells
and  by
41 ± 3 (s.d.) % in 2008/C13*5.25 cells. TPA also increased accumulation of DDP and DWA by 70%, although this effect was limited to the
2008/C13*5.25 cells. TPA rendered 2008 and 2008/C13*5.25 cells resistant to cadmium chloride by a factor of 3.7 and 3.6-fold respectively,
suggesting a significant increase in cellular metallothionein content. Although the mechanism of TPA induced sensitization is not yet fully
understood, this study points to a central role for PKCa in modulating platinum drug sensitivity. © 2000 Cancer Research Campaign
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of PKC-dependent phosphorylation, including alteration of
cellular sensitivity to platinum drugs (Isonishi et al, 1990). Our
previous studies showed that activation of PKC by TPA was able
to circumvent acquired DDP resistance by enhancing sensitivity
to the clinically utilized platinum drugs, with the exception
of (–)-(R)-2-aminomethylpyrrolidine (1,1-cyclobutanedicarboxy-
lato)-platinum (II) monohydrate (DWA), in human ovarian
carcinoma cells (Isonishi et al, 1994a, 1994b). However, it is not
known which isoforms mediate this effect. The aim of the current
study was to investigate the effect of selective down-regulation of
the PKCa isozyme on platinum drug sensitivity.
MATERIALS
DDP and carboplatin (CBDCA) were obtained from the Bristol-
Myers Squibb K.K., Japan. DWA was obtained from the Chugai
Pharmaceutical Co. TPA and cadmium chloride (CdCl2),
leupeptin, and phenylmethanesulphonyl fluoride (PMSF) were
purchased from Sigma Chemical Co. (Tokyo, Japan). Monoclonal
anti-PKC antibodies were purchased from Seikagaku Co., Tokyo,
Japan.
METHODS
Tumour cell lines
The human cell line 2008 was established from a patient with a
serous cystadenocarcinoma of the ovary (Disaida et al, 1972). A
resistant subline, designated 2008/C13*5.25, was obtained by 13
monthly selections with 1 mM DDP (Andrews et al, 1985). The
cells were grown on tissue culture dishes in a humidified incubator
at 37°C and 5% carbon dioxide atmosphere.
TPA treatment and colony assays
Colony forming assays were used to assess the effect of TPA on
the sensitivity of each drug. Five millilitres of cell suspension,
containing 600 cells, were plated on 60-mm polystyrene tissue
culture dishes (Corning Glass Works, Corning, NY, USA). Drug
solution was added to triplicate plates at each drug concentration.
After a 48 h pre-incubation in the presence or absence of 0.1 mM
TPA followed by 1 h exposure to platinum with or without TPA,
the drug-containing medium was aspirated and replaced with
drug-free medium. After 10 days colonies of over 60 cells were
counted macroscopically.
Calculation of IC50 values and enhancement factors
IC50 was defined as the drug concentration reducing the number of
colonies by 50% and was determined by linear regression analysis
of the data. The change in drug sensitivity was expressed as the
ratio of the IC50 values for the control and TPA-treated cells.
Platinum accumulation
Subconfluent monolayers were treated with 37°C RPMI-1640
medium containing 120 mM DDP or DWA. After a 1 h exposure,
the cells were washed rapidly with 4°C phosphate-buffered saline
(PBS) four times. Two millilitres of 1 N sodium hydroxide was
added and the cells were allowed to digest. A 20 ml aliquot was
used for determination of protein content by the method of
Bradford (1976), and the remaining was analysed in an atomic
absorption spectrometer (Hitachi, Z 8000).
Preparation of cell lysates and subcellular fractions
Subconfluent 2008 and 2008/C13*5.25 cells grown in 150-mm
tissue culture dishes were used to prepare cell lysates for determi-
nation of PKC content. After incubation for 48 h in the presence or
absence of 0.1 mM TPA, monolayers of cells were rapidly rinsed
twice with ice-cold PBS and lysed with buffer solution containing
50 mM Tris–HCl, 5 mM EDTA, 10 mM EGTA, 0.1 mM leupeptin,
0.3% (w/v) mercaptoethanol, and 50 mg ml–1 phenylmethane-
sulphonyl fluoride (PMSF). The solubilized cellular material was
harvested by scraping from culture dishes then centrifuged at
12 000 g for 5 min at 4°C. Supernatant samples were stored at
–70°C until used. For the preparation of membrane and cytosolic
subcellular fractions the scraped material was sonicated for 30 s at
4°C and then centrifuged at 100 000 g for 60 min at 4°C. The
isolated supernatant sample was designated the cytosolic fraction.
The precipitated material was subsequently sonicated and desig-
nated the membrane-associated fraction.
Western blot analysis of PKC
Cell extracts were boiled for 5 min and fractionated using sodium
dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE)
minigels (7.5% separating gel) followed by electrotransfer to
nitrocellulose paper. The blots were incubated with 1 mg ml–1 of
mouse anti-PKC monoclonal antibodies specific for the a, b, g, d,
e, m and z isotypes followed by horseradish peroxidase conjugated
anti-mouse Ig (1:4000 dilution).
Assay of PKC activity
PKC activity was measured using a kit (Amersham, RPN 77A).
The reaction was initiated by addition of 25 ml of protein sample to
a reaction mixture containing 12 mM calcium acetate, 50 mM Tris–
HCl, 0.05% (w/v) sodium azide (pH 7.5), 8 mole% La phos-
phatidyl-L-serine, 900 mM peptide substrate, 150 mM magnesium
[32P]ATP, 45 mM magnesium acetate, 30 mM dithiothreitol in a
total volume of 75 ml. After incubation for 15 min at 25°C,
aliquots of the reaction mixture were spotted onto the binding
paper squares, and the squares were placed in 75 mM ortho-
phosphoric acid for 10 min. Radioactivity retained on the papers
was determined. The 32P incorporated into the synthetic peptide,
quantitatively measured by counting the radioactivity of the
binding papers, is a direct measure of PKC activity which was
expressed as 32P incorporated min–1 mg–1 protein.
Measurement of GSH content
GSH content was measured as previously reported (Reed et al,
1980). After the monolayers were incubated in the presence or
absence of TPA for 48 h, the cell pellets were prepared and
incubated in the dark for 15 min. An equal volume of 4 M sodium
methane sulphonate was added to each tube, which was then
frozen until assayed by high performance liquid chromatography
(HPLC).
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Effect of TPA on platinum drug sensitivity
The data presented in Table 1 show that 48 h pretreatment of the
DDP-sensitive 2008 and DDP-resistant 2008/C13*5.25 cells with
0.1 mM TPA increased cellular sensitivity to DDP by a factor of
2.8 ± 0.5 and 2.2 ± 0.4 (standard deviation (s.d.) n = 4) (P < 0.01)
respectively. TPA also enhanced sensitivity to CBDCA in both cell
lines to the same extent as for DDP. The sensitization effect was
dependent on TPA concentration and the maximum sensitization
effect was achieved with as little as 0.05 mM TPA. TPA was also
able to enhance cellular sensitivity to DWA by a factor of
2.2  ± 0.2-fold in 2008 cells and 1.9 ± 0.1-fold in 2008/C13*5.25
cells (s.d.; n = 4) (P < 0.01).
PKC isoform analysis
2008 cells express only the a and z isoforms of PKC. To determine
whether TPA sensitization was related to changes in the level of
either of these two isoforms, a Western blot analysis of total cell
extracts was carried out using PKC antibodies specific for either
PKCa or PKCz. Figure 1 shows that a 48 h exposure to TPA
reduced the PKCa levels in both the 2008 and 2008/C13*5.25
cells. Densitometric analysis of the bands showed that TPA
decreased the expression of PKCa to 60.3 ± 4.4% of control in
2008 cells and to 45.0 ± 2.8% (s.d.; n = 3) (P < 0.01) in
2008/C13*5.25 cells. In contrast, TPA exposure had no effect on
the level of PKCz. It thus appears that, in these two cell lines, there
was a differential effect of TPA on these two isoforms.
Time course of PKC activity
To better characterize the changes in PKC activity found in 2008
cells, the subcellular distribution of PKC activity was determined
as a function of time after the start of exposure to 0.1 mM TPA.
Figure 2 shows that during the first 6 h there was a rapid loss of
PKC activity from the cytosolic fraction. Concomitantly, there was
a prompt increase in plasma membrane-associated PKC activity.
With continued exposure there was a progressive decrease in the
membrane-associated activity, and recovery of the cytosolic
activity to above baseline level by 48 h.
Effect of TPA on cellular platinum accumulation
Table 1 Effect of TPA on sensitivity to DDP, CBDCA, and DWA
IC501
Enhancement
Drug Cell TPA treatment facter2
(–) 48 hr (-fold)
DDP 2008 3.1 ± 0.6 1.1 ± 0.2 2.8 ± 0.6
C13*53 13.6 ± 2.7 6.3 ± 1.2 2.2 ± 0.4
CBDCA 2008 22.6 ± 5.8 7.9 ± 0.8 2.9 ± 0.7
C13*5 107.4 ± 0.3 20.9 ± 5.2 5.1 ± 0.0
DWA4 2008 118.9 ± 9.8 53.7 ± 8.8 2.2 ± 0.2
C13*5 42.6 ± 1.8 22.5 ± 6.8 1.9 ± 0.1
1 50% Inhibitory concentration; mM, mean ± s.d. 2 Enhancement factor = IC50
(control)/IC50 (TPA). 3 2008/C13*5.25. 4 DWA.
2008 2008/C13*5.25
TPA –      + –      + –      + –      +
PKCa
PKCz
TPA
2008/C13*5.25 2008
Figure 1 Effect of TPA on PKC expression. PKC was extracted from 2008
and 2008/C13*5.25 cells, then Western blot analyses were performed using
polyclonal antisera specific to PKCa and PKCz. Densitometric analysis
showed that TPA decreased the expression of PKCa to 60.3 ± 4.4% of
control in 2008 cells and to 45.0 ± 2.8% (s.d.; n = 3) (P < 0.01) in
2008/C13*5.25 cells. TPA exposure had no effect on the level of PKCz
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Figure 2 Time course of PKC activity in 2008 cells. Membrane (solid
circles) and cytosol (open circles) associated PKC activity in 2008 cells
treated with 0.1 mM TPA for various periods of time. Points, mean values
of 3 experiments performed with triplicate cultures; bars, s.d. Asterisks,
P < 0.05 compared to the control at the same time point
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Figure 3 Effect of TPA on cellular platinum accumulation. Platinum content
after a 1 h exposure to either 120 mM DDP or DWA alone (hatched bars) or
after a concurrent 1 h exposure to 0.1 mM TPA with either 120 mM DDP or
DWA following 48 h pre-incubation in the presence of 0.1 mM TPA (open
bars). In 2008/C13*5.25 cells TPA increased DDP accumulation by 1.8 ± 0.3
(s.d.; n = 4)-fold and DWA accumulation by 1.7 ± 0.2 (s.d.;
n = 4)-fold (P < 0.01) (B and D)Enhancement of platinum sensitivity 37
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Cells were pre-incubated with 0.1 mM TPA for 24 or 48 h and then
with either DDP or DWA for 1 h. TPA did not modulate the
cellular accumulation of either DDP or DWA in 2008 cells at
either time point. However, in the 2008/C13*5.25 cells TPA
increased DDP accumulation at both time points to the same
degree by 1.8 ± 0.3 (s.d.; n = 4)-fold and DWA accumulation by
1.7 ± 0.2 (s.d.; n = 4)-fold (Figure 3, B, D) (P < 0.01 for both).
Thus, TPA-mediated sensitization was associated with an increase
in drug accumulation in the DDP-resistant 2008/C13*5.25 cells
but not the DDP-sensitive 2008 cells.
Effect of TPA on cellular GSH and MT content
Changes in GSH and MT levels are among several other mecha-
nisms that have been reported to modulate DDP sensitivity. Figure
4 shows the cellular GSH content measured by HPLC analysis.
TPA treatment significantly decreased GSH level by 30 ± 3
(s.d.)% in the 2008 cells and by 41 ± 3 (s.d.)% in 2008/C13*5.25
cells, an effect consistent with enhanced sensitivity to DDP. In
contrast, TPA rendered 2008 and 2008/C13*5.25 cells resistant to
CdCl2 by 3.7 ± 1.1 (s.d.)-fold and 3.6 ± 0.7 (s.d.)-fold, suggesting
a substantial increase in cellular MT content, an effect that would
be expected to reduce rather than increase sensitivity to DDP.
DISCUSSION
Several lines of evidence indicate that modulation of PKC activity
can alter cellular sensitivity to cytotoxic agents. Results of cyto-
toxicity studies in which PKC activity was down-regulated with
either TPA or the inhibitor H-7 (1-5-isoquinolinesulphonyl)-2-
methylpiperazine) indicate a close relationship between PKC
activity and cellular sensitivity to several classes of anticancer
drugs (Fine et al, 1988; Basu et al, 1990; Isonishi et al, 1994).
P-glycoprotein, which mediates resistance to many chemothera-
peutic drugs, has been reported to be a good substrate for PKC
(Chambers et al, 1990), and enhanced phosphorylation of this
protein has been noted following phorbol ester treatment.
However the cells we have used in this experiments did not
express P-glycoprotein at detectable levels as determined by
Western blot (data not shown). The fact that sensitivity to several
different classes of drugs with different cytotoxic mechanisms is
affected suggests that PKC works through several different path-
ways to alter drug sensitivity.
One of the major findings of the current study is that TPA selec-
tively down-regulated the level of PKCa but not that of PKCz in
2008 cells. This documents a differential effect of TPA on at least
these two isoforms, and directs attention to PKCa as a candidate
mediator of the TPA effect on DDP sensitivity. A recent report
using antisense cDNA against PKCa and PKCb1 has demon-
strated that only PKCa mediates the phorbol ester activation of
phospholipase D in Madin-Darby canine kidney D1 cells (Balboa
et al, 1994). This is consistent with our observation that PKCa was
responsive to TPA treatment in the 2008 cells. Total membrane
associated PKC activity was not completely down-regulated even
after a 48 h exposure to TPA probably because PKCz activity was
not altered by this treatment. As yet it is not possible to selectively
measure just PKCa activity. Such a measurement would enable
one to directly test whether the relatively small changes observed
in the level of PKCa reflect a change in actually commensurate
with the change in sensitivity to DDP.
The cell line used in this study expressed a limited number of
PKC isozymes. As has been reported previously (Isonishi et al,
1994) electrophoretic analysis with antisera specific for the a, b, g,
d, e, m and z isotypes of PKC indicated that a- and z-isotype PKC
(PKCa and z) were the dominant forms present in both 2008 and
2008/C13*5.25 cells, whereas none of the other isoforms could be
identified in these cells. Cell lines that express other specific PKC
isozymes should be tested to determine whether other isoforms are
involved in regulating platinum drug sensitivity. One of the major
challenges in identifying exactly how TPA modulates drug sensi-
tivity is the fact that PKC has multiple substrates, and is involved
in several different signalling pathways (Rapp et al, 1991; Bruder
et al, 1992; Kolch et al, 1993; Chmura et al, 1966; Blagosklonny
et al, 1997) through its ability to initiate phosphorylation cascades
(McCaffrey et al, 1987; Smeal et al, 1992; Fung et al, 1997).
Sorting out which isoforms are modulated by TPA, and which can
mediate enhanced DDP sensitivity, should permit identification of
the most important signal transduction pathways involved.
Our studies also indicate that the effect of TPA varies with the
underlying DDP-sensitivity of the cell. While TPA enhanced the
DDP sensitivity to almost the same degree in the 2008 and
2008/C13*5.25 cells, the mechanisms by which it accomplished
this were not the same. TPA increased DDP uptake in the resistant
but not in the sensitive cells. This is of particular interest because
impaired uptake of DDP is one of the major mechanisms of DDP
resistance in the 2008/C13*5.25 cells. It has been postulated that
DDP accumulation is partly due to passive diffusion and partly due
to facilitated diffusion through a gated channel, and that reduced
DDP accumulation in resistant cells may result from inactivation
of a channel protein (Gately, 1993). The fact that TPA can
modulate DDP uptake provides another piece of evidence indi-
cating that uptake is regulatable, and supports the hypothesis that
the signal transduction pathway activated by TPA in the
2008/C13*5.25 cells links to the molecular mechanism that
regulates DDP accumulation.
Elevated levels of GSH, the major intracellular non-protein
thiol, have been observed in human ovarian carcinoma cells with
acquired DDP-resistance (Godwin, 1992). Likewise, on the basis
of experiments in mice in which the gene has been knocked out,
the level of MT, the major intracellular protein thiol, has been
reported to play an important role in controlling DDP sensitivity
(Kondo, 1995). Over-expression of MT has been observed in a
number of human tumour cell lines with acquired DDP-resistance
2008 2008/C13*5.25
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Figure 4 Effect of TPA on GSH content. Intracellular GSH content in 2008
and 2008/C13*5.25 cells immediately after a 48 h pre-incubation in the
presence (solid bars) or absence (hatched bars) of 0.1 mM TPA. Bars, mean
of 3 independent experiments, each with duplicate cultures; bars, SD. TPA
treatment decreased GSH level by 30 ± 3 (s.d.)% (P < 0.01) in 2008 cells
and by 41 ± 3 (s.d.)% (P < 0.01) in 2008/C13*5.25 cells38 S Isonishi et al
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(Kelly, 1988). In our experiments, TPA treatment produced a
substantial decrease in GSH level, but changes in CdCl2 sensitivity
indicative of an increase in MT level. It is hard to know whether
either of these effects participated in changing DDP sensitivity, or
whether they just neutralized each other. Likewise, it is not clear
whether either effect results from a direct biochemical action of
TPA or an indirect effect mediated via activation of PKC.
Although we did not measure the effect of TPA on platinum-DNA
adduct formation, based on prior studies an 80% increase in
platinum accumulation combined with a 40% decrease in GSH
content would not appear to be of sufficient magnitude to account
for two- to fivefold increase in sensitivity to the various platinum
drugs tested. This lack of correlation is likely due to the involve-
ment of multiple mechanisms in the regulation of platinum drug
sensitivity.
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